Breast Cancer Articles | Page 3

Trastuzumab Deruxtecan Impresses in HER2 Expressing Breast Cancers
Trastuzumab deruxtecan (ds-8201a), a HER2-targeting antibody-drug conjugate, demonstrated significant clinical activity in heavily pretreated patients with HER2-expressing metastatic breast cancers.
Positive CTC Findings Linked to High Recurrence Risk in HR+ Breast Cancer
Detection of positive circulating tumor cells in the blood 5 years after a breast cancer diagnosis was associated with an increased risk for late recurrence in women with HR–positive, HER2-negative breast cancer
Pembrolizumab/Eribulin Efficacy Maintained for TNBC in Larger Dataset
Treatment with the combination of pembrolizumab (Keytruda) and eribulin (Halaven) demonstrated a 26.4% objective response rate for patients with metastatic triple-negative breast cancer.
Even Moderate Weight Loss Helps Prevent Breast Cancer in Postmenopausal Women
Losing even some extra weight significantly reduces the risk of breast cancer for postmenopausal women, expert says. 
Neoadjuvant Abemaciclib Active in Early Breast Cancer
Neoadjuvant treatment with abemaciclib (Verzenio) plus anastrozole induced complete cell cycle arrest as measured by Ki67 for 67.8% of patients with HR-positive/HER2-negative early-stage breast cancer.
CDK4/6 Improved PFS in Older Women with HR+ Metastatic Breast Cancer
Older women with HR–positive breast cancer treated with a CDK4/6 inhibitor may derive a progression-free survival  benefit similar to that seen in their younger counterparts
Talazoparib Improves PFS in BRCA-Positive Breast Cancer
The PARP inhibitor talazoparib reduced the risk of disease progression or death by 46% versus chemotherapy in patients with BRCA-positive advanced breast cancer.
Nab-Paclitaxel Improves DFS Over the Long Term in Early Breast Cancer
Substituting nab-paclitaxel (Abraxane) for solvent-based paclitaxel as neoadjuvant chemotherapy improved disease-free survival in patients with high-risk early breast cancer.
Nab-Paclitaxel Shows Greatest Utility for TNBC
Treatment with nab-paclitaxel showed promising improvements in overall survival and progression-free survival compared with standard paclitaxel for patients with metastatic triple-negative breast cancer. 
No Difference in Overall Survival with Shorter Extended AI Therapy
Investigators with the Austria Breast and Colorectal Cancer Study Group announced today that years can safely be shaved off anastrozole (Arimidex) treatment without affecting disease-free survival postmenopausal HR-positive breast cancer.
Publication Bottom Border
Border Publication